Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00305396 · ClinicalTrials.gov registry record · Phase 4
Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation
A Phase 4 study of Kidney Transplantation, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 4
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00305396 is a Phase 4 study of Kidney Transplantation that has completed, run by Vanderbilt University. The registered enrollment target is 80 participants, below the 266-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00305396, a Phase 4 study of Kidney Transplantation, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, single center, open-label, randomized trial of Thymoglobulin induction and sirolimus, prednisone, and mycophenolate mofetil versus Thymoglobulin induction and tacrolimus, prednisone, and mycophenolate mofetil in non-HLA identical living or deceased donor kidney transplant recipients.
Conditions Studied
Interventions
- DRUG Sirolimus
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center/Nashville VA - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-04 |
| Est. Completion | 2005-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00305396
The ClinicalTrials.gov registry entry for NCT00305396 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 266-participant average among 33 other Kidney Transplantation trials with a reported enrollment target (70% lower). The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Sirolimus is the first listed.
NCT00305396 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00305396 about?
NCT00305396 is a clinical study titled "Calcineurin Inhibitor Avoidance With Thymoglobulin and Sirolimus in Kidney Transplantation". A prospective, single center, open-label, randomized trial of Thymoglobulin induction and sirolimus, prednisone, and mycophenolate mofetil versus Thymoglobulin induction and tacrolimus, prednisone, and mycophenolate mofetil in non-HLA identical living or deceased donor kidney transplant recipients.
What is the current status of trial NCT00305396?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 80 participants. The study started on 2004-04. Estimated completion is 2005-03.
What conditions does trial NCT00305396 study?
This clinical trial studies the following conditions: Kidney Transplantation.
What interventions are being tested in trial NCT00305396?
The interventions under investigation include: Sirolimus (DRUG).
Who is sponsoring clinical trial NCT00305396?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00305396 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective, Randomized, Multicenter Trial.
RECRUITING · Phase 4
-
Envarsus XR® in Adolescent Renal Transplant Recipients
ACTIVE NOT RECRUITING · Phase 4
-
Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients
COMPLETED · Phase 4
-
Study of Therapeutic Monitoring of Mycophenolate Mofetil (MMF/CellCept) After Kidney Transplantation
COMPLETED · Phase 4
-
Shared Decision Making for Kidney Transplant Candidates to Plan for an Organ Offer Decision
RECRUITING · NA
-
Prehabilitation for Kidney Transplant Candidates
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.